AC Immune (NASDAQ:ACIU – Get Free Report) was downgraded by Zacks Research from a “strong-buy” rating to a “hold” rating in a research note issued on Wednesday, Zacks reports.
Other research analysts also recently issued research reports about the company. HC Wainwright reiterated a “buy” rating on shares of AC Immune in a report on Thursday, September 24th. BTIG Research restated a “buy” rating and set a $8.00 target price on shares of AC Immune in a research note on Wednesday, September 23rd. Finally, Weiss Ratings downgraded AC Immune from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, October 20th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $7.50.
View Our Latest Research Report on AC Immune
AC Immune Price Performance
Shares of ACIU opened at $2.37 on Wednesday. AC Immune has a 1-year low of $2.03 and a 1-year high of $3.90. The stock has a market cap of $241.20 million, a PE ratio of -4.39 and a beta of 1.56. The firm has a 50-day simple moving average of $2.62 and a two-hundred day simple moving average of $2.74.
AC Immune (NASDAQ:ACIU – Get Free Report) last released its earnings results on Thursday, August 6th. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.13. The company had revenue of $18.67 million during the quarter, compared to the consensus estimate of $9.59 million. AC Immune had a negative return on equity of 100.17% and a negative net margin of 245.32%. As a group, sell-side analysts expect that AC Immune will post -0.60 earnings per share for the current fiscal year.
Hedge Funds Weigh In On AC Immune
Large investors have recently bought and sold shares of the stock. Arrowstreet Capital Limited Partnership grew its holdings in shares of AC Immune by 8.0% during the first quarter. Arrowstreet Capital Limited Partnership now owns 405,658 shares of the company’s stock worth $1,116,000 after purchasing an additional 30,035 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of AC Immune by 82.8% during the first quarter. Dimensional Fund Advisors LP now owns 390,165 shares of the company’s stock worth $1,071,000 after purchasing an additional 176,701 shares in the last quarter. Finally, AXQ Capital LP purchased a new stake in shares of AC Immune in the 2nd quarter valued at about $25,000. Institutional investors and hedge funds own 51.36% of the company’s stock.
AC Immune Company Profile
AC Immune SA is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, focused on developing treatments and diagnostic products for neurodegenerative diseases. Its research primarily addresses Alzheimer’s disease, Parkinson’s disease and related disorders by targeting proteins believed to contribute to disease progression, including amyloid and tau.
The company’s technology platforms include SupraAntigen, which supports the discovery of antibodies and vaccines, and Morphomer, which is used to identify small-molecule compounds that may prevent or modify the abnormal aggregation of disease-associated proteins.
Featured Stories
- Five stocks we like better than AC Immune
- Robinhood Stock Is Down Nearly 37%—So Why Is Wall Street Still So Bullish?
- 5 Stocks to Buy in November: Bargains Worth Giving Thanks For
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.
